BIT Capital GmbH Purchases New Shares in COMPASS Pathways plc (NASDAQ:CMPS)

BIT Capital GmbH purchased a new position in shares of COMPASS Pathways plc (NASDAQ:CMPS) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 115,697 shares of the company’s stock, valued at approximately $437,000. BIT Capital GmbH owned 0.17% of COMPASS Pathways at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Conservest Capital Advisors Inc. increased its stake in COMPASS Pathways by 28.9% in the 4th quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth $41,000. Wealthfront Advisers LLC purchased a new stake in shares of COMPASS Pathways in the fourth quarter valued at about $43,000. Flagship Harbor Advisors LLC acquired a new position in shares of COMPASS Pathways during the fourth quarter worth about $43,000. Finally, Franklin Resources Inc. lifted its position in COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after purchasing an additional 12,599 shares during the period. 46.19% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Stifel Nicolaus assumed coverage on COMPASS Pathways in a research report on Thursday, February 27th. They set a “buy” rating and a $11.00 target price on the stock. Canaccord Genuity Group cut their price target on COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating for the company in a report on Friday, February 28th. HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of COMPASS Pathways in a report on Tuesday, March 4th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, COMPASS Pathways presently has an average rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Stock Down 2.9 %

CMPS opened at $2.98 on Thursday. COMPASS Pathways plc has a one year low of $2.85 and a one year high of $10.31. The company has a market capitalization of $276.17 million, a PE ratio of -1.35 and a beta of 2.29. The stock’s fifty day moving average is $3.88 and its 200-day moving average is $4.77. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities analysts predict that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.